{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:47:17Z","timestamp":1759333637792},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,6,1]]},"DOI":"10.1086\/313851","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T18:58:36Z","timestamp":1027709916000},"page":"S193-S197","source":"Crossref","is-referenced-by-count":30,"title":["Rationale for the Use of Hydroxyurea as an Anti-Human Immunodeficiency Virus Drug"],"prefix":"10.1093","volume":"30","author":[{"given":"Franco","family":"Lori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julianna","family":"Lisziewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2000,6]]},"reference":[{"key":"key\n\t\t\t\t20171014004209_R1","first-page":"11","article-title":"An overview of the clinical experience with hydroxyurea","volume":"19","author":"Donehower","year":"1992","journal-title":"Semin Oncol"},{"key":"key\n\t\t\t\t20171014004209_R2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/0140-6736(90)92085-V","article-title":"Long-term toxicity\/activity profile of 2\u2032,3\u2032-dideoxyinosine (didanosine) in AIDS or AIDS-related complex","volume":"336","author":"Yarchoan","year":"1990","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171014004209_R3","doi-asserted-by":"crossref","first-page":"11017","DOI":"10.1073\/pnas.91.23.11017","article-title":"Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2\u2032,3\u2032-dideoxyinosine in infected resting human lymphocytes","volume":"91","author":"Malley","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20171014004209_R4","first-page":"21","article-title":"The evolution of hydroxyurea therapy in chronic myelogenous leukemia","volume":"19","author":"Kennedy","year":"1992","journal-title":"Semin Oncol"},{"key":"key\n\t\t\t\t20171014004209_R5","first-page":"253","article-title":"Hydroxyurea","volume-title":"Cancer chemotherapy and biotherapy","author":"Donehower","year":"1996","edition":"2d ed."},{"key":"key\n\t\t\t\t20171014004209_R6","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014004209_R7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1128\/AAC.3.3.325","article-title":"Reversible inhibition of herpes simplex virus replication by hydroxyurea","volume":"3","author":"Rosenkranz","year":"1973","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014004209_R8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0042-6822(73)90142-6","article-title":"Studies on the mechanism of replication of adenovirus DNA. I. The effect of hydroxyurea","volume":"54","author":"Sussenbach","year":"1973","journal-title":"Virology"},{"key":"key\n\t\t\t\t20171014004209_R9","first-page":"1686","article-title":"Effects of hydroxyurea on polyoma virus replication","volume":"28","author":"Nordenskj\u00f6ld","year":"1968","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t20171014004209_R10","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.2418502","article-title":"Long-term cultures of HTLV-III-infected T cells: a model of cytopathology of T-cell depletion in AIDS","volume":"231","author":"Zagury","year":"1986","journal-title":"Science"},{"key":"key\n\t\t\t\t20171014004209_R11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0092-8674(90)90802-L","article-title":"HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure","volume":"61","author":"Zack","year":"1990","journal-title":"Cell"},{"key":"key\n\t\t\t\t20171014004209_R12","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/j.1460-2075.1990.tb08274.x","article-title":"HIV-1 replication is controlled at the level of T cell activation and proviral integration","volume":"9","author":"Stevenson","year":"1990","journal-title":"EMBO J"},{"key":"key\n\t\t\t\t20171014004209_R13","doi-asserted-by":"crossref","first-page":"8925","DOI":"10.1073\/pnas.90.19.8925","article-title":"Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication","volume":"90","author":"Gao","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20171014004209_R14","doi-asserted-by":"crossref","first-page":"16037","DOI":"10.1016\/S0021-9258(18)66672-4","article-title":"Changes of deoxyribonucleotide triphosphate pools induced by hydroxyurea and their relation to DNA synthesis","volume":"261","author":"Bianchi","year":"1986","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20171014004209_R15","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.7973634","article-title":"Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication","volume":"266","author":"Lori","year":"1994","journal-title":"Science"},{"key":"key\n\t\t\t\t20171014004209_R16","first-page":"767","article-title":"Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2\u2032,3\u2032-dideoxynucleosides","volume":"46","author":"Gao","year":"1994","journal-title":"Mol Pharmacol"},{"key":"key\n\t\t\t\t20171014004209_R17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF01880662","article-title":"Metabolism and mechanism of antiviral action of purine and pyrimidine derivatives","volume":"16","author":"Balzarini","year":"1994","journal-title":"Pharm World Sci"},{"key":"key\n\t\t\t\t20171014004209_R18","first-page":"322","article-title":"The distribution, excretion, and metabolism of hydroxyurea-C14","volume":"150","author":"Adamson","year":"1965","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t20171014004209_R19","first-page":"57","article-title":"Hydroxyurea in biologic fluids: dose-concentration relationship","volume":"48","author":"Beckloff","year":"1965","journal-title":"Cancer Chemother Rep"},{"key":"key\n\t\t\t\t20171014004209_R20","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1128\/AAC.41.2.460","article-title":"Increased activation of the combination of 3\u2032-azido-3\u2032-deoxythymidine and 2\u2032-deoxy-3\u2032-thiacytidine in the presence of hydroxy-urea","volume":"41","author":"Palmer","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014004209_R21","doi-asserted-by":"crossref","first-page":"8333","DOI":"10.1073\/pnas.92.18.8333","article-title":"Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2\u2032,3\u2032-dideoxynucleoside activities against replication of human immunodeficiency virus","volume":"92","author":"Gao","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20171014004209_R22","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1089\/aid.1997.13.1403","article-title":"Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance","volume":"13","author":"Lori","year":"1997","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20171014004209_R23","doi-asserted-by":"crossref","first-page":"F71","DOI":"10.1097\/00002030-199808000-00003","article-title":"A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV-1 infection","volume":"12","author":"Rutschmann","year":"1998","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171014004209_R24","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(97)24035-3","article-title":"Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide","volume":"350","author":"Vila","year":"1997","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171014004209_R25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0140-6736(98)24029-3","article-title":"HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor","volume":"352","author":"Lisziewicz","year":"1998","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171014004209_R26","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1056\/NEJM199905273402114","article-title":"Control of HIV despite the discontinuation of antiretroviral therapy","volume":"340","author":"Lisziewicz","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014004209_R27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1126\/science.271.5248.497","article-title":"Reduction of HIV concentration during acute infection: independence from a specific immune response","volume":"271","author":"Phillips","year":"1996","journal-title":"Science"},{"key":"key\n\t\t\t\t20171014004209_R28","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00002030-199105000-00002","article-title":"Population dynamics of HIV within an individual after treatment with zidovudine","volume":"5","author":"McLean","year":"1991","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171014004209_R29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-199201000-00009","article-title":"Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV","volume":"6","author":"McLean","year":"1992","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171014004209_R30","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1073\/pnas.93.11.5501","article-title":"Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine","volume":"93","author":"de Jong","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20171014004209_R31","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1097\/00002030-199813000-00002","article-title":"Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine","volume":"12","author":"De Boer","year":"1998","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171014004209_R32","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJM199810293391801","article-title":"Maintenance antiretroviral therapies in HIV-infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team","volume":"339","author":"Havlir","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014004209_R33","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1126\/science.274.5292.1543","article-title":"T cell telomere length in HIV-1 infection: no evidence for increased CD4+ T cell turnover","volume":"274","author":"Wolthers","year":"1996","journal-title":"Science"},{"key":"key\n\t\t\t\t20171014004209_R34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1126\/science.271.5246.173","article-title":"Immunology taught by viruses","volume":"271","author":"Zinkernagel","year":"1996","journal-title":"Science"},{"key":"key\n\t\t\t\t20171014004209_R35","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/0167-5699(94)90005-1","article-title":"T-cell-mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS","volume":"15","author":"Zinkernagel","year":"1994","journal-title":"Immunol Today"},{"key":"key\n\t\t\t\t20171014004209_R36","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1086\/313856","article-title":"Title","volume":"30","author":"Zala","year":"2000","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/30\/Supplement_2\/S193\/20903963\/30-Supplement_2-S193.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T08:51:13Z","timestamp":1621241473000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/30\/Supplement_2\/S193\/373680\/Rationale-for-the-Use-of-Hydroxyurea-as-an"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,6,1]]},"references-count":36,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2000,6]]},"published-print":{"date-parts":[[2000,6,1]]}},"URL":"https:\/\/doi.org\/10.1086\/313851","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2000,6]]},"published":{"date-parts":[[2000,6,1]]}}}